To see what you can do, look inside.
| |
Dear Reader,
Look at this chart from 1999… during the last great "Melt Up."
As you can see, almost all the gains happened in the last 6 months of the boom…
ALL in tech and biotech stocks…
Bottom-line: This is where you want to put your money right now.
On my own, I've recommended several tech and biotech funds. And we've done well…
But if you're the type of person who's looking for tiny but volatile stocks that can go up 500% or more… then I urge you to check out what my colleague Dave Lashmet is doing on Wednesday night. And what he's recommending.
Dave was the first analyst Porter and I hired back in 2000.
He's one of the smartest guys I know.
And his track record speaks for itself: He just found his eighth 100% gain in his latest venture… and has an open position currently up over 350%.
The thing is, Dave doesn't normally hold live events like Porter and I do.
But on Wednesday night, November 15th, this live event will be his first ever.
And frankly, I've never seen him so excited about a recommendation.
The company Dave will discuss on Wednesday has just made a dramatic breakthrough in cancer medicine. He predicts it could improve survival rates for millions of people… and send the stock behind it soaring.
So if you're looking for some truly massive gains in the next few months, Dave's event this coming Wednesday is a must-see.
To see what Dave is doing on Wednesday, November 15th, and to receive free access, click here.
Good Investing,
Dr. Steve Sjuggerud
P.S. If history has taught us anything… it's that the money you could make on cancer breakthroughs like this is staggering.
* For example, Celgene (CELG) developed a tumor drug called Revlimid. For every $500 you invested in 2004… you'd be sitting on over $9,200 today. A 1,700% gain. * Incyte (INCY) discovered a new treatment for myelofibrosis. You'd be sitting on more than a 500% gain right now if you had invested just before their first breakthrough. * Kite Pharma (KITE), is up more than 300% this year… after the FDA approved its first-ever gene therapy drug, Kymriah. But the best part is, the biotech company Dave has uncovered doesn’t just treat one type of cancer… but all cancers. In just 60 minutes.
To learn more, click here. |
|
| |
All contents of this e-mail are copyright 2017 by Stansberry Research. All rights reserved. Reproducing any part of this document is prohibited without the express written consent of Porter Stansberry. Protected by U.S. Copyright Law {Title 17 U.S.C. Section 101 et seq., Title 18 U.S.C. Section 2319}: Infringements can be punishable by up to five years in prison and $250,000 in fines.
DISCLAIMER: The work included in this publication is based on SEC filings, current events, interviews, and corporate press releases. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility. The views expressed in this publication do not necessarily reflect the views of Stansberry Research.
You're receiving this email at [email protected]. If you have any questions about your subscription, or would like to change your email settings, please contact Stansberry Research at (888) 261-2693 Monday-Friday between 9:00 a.m. and 5:00 p.m. Eastern Time. Or if calling internationally, please call 443-839-0986. Stansberry Research, 1125 N Charles Street Baltimore, MD 21201. If you wish to contact us by email, please do not reply to this message but instead go to [email protected].
To unsubscribe from this mailing, click here: Unsubscribe
|
|
|
